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Abstract
In this chapter, we focus on the medical treatment of overactive bladder (OAB) syn‐
drome. The treatment of choice of the OAB syndrome is still the anticholinergic therapy, 
although we must consider β3‐agonists with almost the same evidence. No drug has been 
shown to be clearly superior to the rest. The use of oxybutynin transdermal should be 
considered when the side effects due to the oral administration are intolerable. In elderly 
patients, first efforts should be directed to use non‐drug therapies, such as behavioural 
therapy. In patients suffering from cognitive dysfunctions, the use of antimuscarinic with 
caution is recommended. Mirabegron, a β3‐agonist, can be offered, although it should 
be noted that the long‐term effects are still unknown. The logical second‐line treatment 
is the intravesical injection of botulinum toxin A, considering its temporary effective‐
ness and the possibility of retention. In some centres, sacral nerve stimulation may be an 
option. Surgical treatment should be reserved when conservative therapies fail.
Keywords: medical treatment, overactive bladder, antimuscarinics
1. Introduction
Overactive bladder or detrusor overactivity is characterized by the presence of involuntary 
detrusor contractions that may be spontaneous or provoked [1]. Clinically, idiopathic detru‐
sor overactivity is manifested as the urgent desire to urinate, with or without incontinence, 
generally associated with frequency and nocturia, which severely affect patients’ quality of 
life. This combination of symptoms is included in a more general term that we know of as 
overactive bladder (OAB) [2].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
When designing a treatment algorithm, the balance between the risks and benefits of each 
option must be taken into account regarding effectiveness and invasiveness, and the duration, 
severity and reversibility of adverse effects, more so than the evidence available. Behavioural 
treatment or hygienic‐dietetic measures, that is, pelvic floor rehabilitation exercises and blad‐
der training, are considered to be the first line of treatment for OAB syndrome, although they 
require great amount of time and effort from both the physician and the patient [3]. Oral and 
transdermal drugs are the second line of treatment, where antimuscarinic agents, in spite of 
their effectiveness, present a high percentage of side effects (all reversible). The third line of 
treatment includes intra‐bladder treatment with onabotulinum toxin A, which entails risks 
of urinary retention with delayed resolution, and the different options of neuromodulation 
and nerve stimulation, which are more invasive and require greater motivation on behalf of 
the patient. And finally, surgery, the last therapeutic option due to its irreversible side effects 
[4] is surgery such as augmentation enterocystoplasty or urinary derivation.
The medical treatment of idiopathic OAB syndrome is the main objective in this chapter.
2. Oral medication
Medical treatment is the second line of treatment of OAB syndrome. It should be high‐
lighted that the efficacy of said treatment is subject to the associated side effects of the drugs 
implemented, which are usually frequent and intense, leading many patients to abandon 
treatment.
In an attempt to inhibit the contractions of the detrusor muscle that occur in OAB syndrome, 
different drugs have been used including anticholinergics, calcium antagonists (nifedipine, 
flunarizine and terodiline hydrochloride), β‐adrenergic agonists (clenbuterol), α‐adrenergic 
blockers (prazosin), prostaglandin‐synthetase inhibitors (indomethacin) and muscle relax‐
ants (flavoxate hydrochloride and dicyclomine) [5]. Of all the aforementioned, the most fre‐
quently used are the antimuscarinic anticholinergic drugs. Recently, a new group of drugs 
has become available, known as β3‐agonists, which present a competitive efficacy and toler‐
ability when compared with the classical treatment.
2.1. Antimuscarinic drugs
Antimuscarinic or anticholinergic drugs are currently used as the primary treatment of OAB 
syndrome. The differences among them are based on their pharmacological profiles (musca‐
rinic receptor affinity and other routes of action), the pharmacokinetic properties (liposolubil‐
ity) and the formulations available.
Antimuscarinic drugs act by blocking the muscarinic receptors that are stimulated by ace‐
tylcholine, which is simultaneously released by the parasympathetic nervous system's activ‐
ity, inhibiting the contraction of the detrusor muscle. The muscarinic receptors are primarily 
found in smooth muscle fibres, including the detrusor muscle, and in glands. Five types of 
muscarinic receptors have been described in human bladders; the most frequent are M2 and 
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M3, with M2 predominant to M3 in a 3:1 ratio. The M2 receptors are responsible for relaxing 
the detrusor muscle. The M3 receptors control the contraction of the detrusor muscle. Close to 
90% of the muscarinic receptors in the salivary glands are of the M3 type [6]. The concomitant 
stimulation of these receptors by the antimuscarinics explains the well‐known adverse effects 
of dry mouth and constipation.
The antimuscarinics can be divided into the following groups:
• Tertiary amines (atropine, oxybutynin, propiverine, darifenacin, tolterodine and solif‐
enacin), which are well absorbed in the gastrointestinal tract, and depending on their 
lipophilic nature, they present a greater or lesser capacity to pass through the blood‐
brain barrier.
• Quaternary amines (propantheline, trospium chloride), which are not well absorbed in 
the digestive tract but have a lower incidence of side effects affecting the central nervous 
system.
Antimuscarinic drugs are metabolized by the cytochrome P450 enzyme system, fundamen‐
tally by the CYP2D6 and CYP3A4 enzymes, with the respective risk of pharmacological inter‐
action by enzymatic induction or inhibition.
Establishing solid criteria regarding the resolution or improvement of urinary urgency associ‐
ated with OAB is difficult. The absence of a standard definition of improvement or worsening 
impedes the possibility of creating a concept of resolution as a primary objective. Generally, 
systematic reviews assert that the effect of pharmacological treatment is weak but signifi‐
cantly superior than that of the placebo.
Antimuscarinics lack complete selectivity at the bladder level and produce side effects in 
other organs and systems that may limit their use [7]. Dryness of the mouth is the most fre‐
quent side effect, although constipation, blurry vision, tachycardia, fatigue or altered cogni‐
tive function may also occur. These side effects are dose‐dependent and thus patients should 
start with a minimal dose and gradually increase depending on the efficacy and the patient's 
tolerance.
The immediate release (IR) formulation of oxybutynin is the prototype drug for urinary 
urgency. It provides adequate flexibility regarding the maximum dose, even when used as 
needed ‘off label'. However, due to its pharmacokinetic properties, the IR drugs have a greater 
risk of side effects than the extended release (ER) versions. The transdermal release system or 
topical gels provide an alternative formulation to be taken into consideration.
2.2. Dosage: pharmacokinetics
The dosage and pharmacokinetics of the primary antimuscarinics used in daily clinical prac‐
tice are presented in Table 1.
All antimuscarinics are contraindicated in patients with closed‐angle glaucoma. On the other 
hand, the use of any antimuscarinic must be taken into account during breastfeeding as it may 
inhibit the production of milk due to its direct effect on the mammary glands.
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Dosage Half life Bioavailability Stable 
concentration time
Excreted in urine Excreted in faeces Other
Oral oxybutynin*1 IR—5 mg/8–12 h
ER—10 mg/24 h
2–3 h 2–11% 8 days 50% 50% –
Transdermal 
oxybutynin*2
36 mh/3–4 days 
(patch)
2–3 h – 48 h <0.1% 99% No first hepatic pass
Tolterodine*3 IR—2 mg/1–2 h
ER—4 mg/24 h
6–10 h 17–65% 4 days 77% 17% –
Solifenacin*4 5 mg/2–4 h
(max 10 mg)
50 h 90% 24 h 70% 23% –
Fesoterodine*7 4 mg/24 h (max 8 
mg)
7 h 52% 24 h 70% 7% No first hepatic pass
*1 Oral oxybutynin. Oxybutynin has been the most used drug for many years to treat OAB. Along with its anticholinergic effect, it acts as an antispasmodic agent, muscle 
relaxant and even as a local anaesthetic, if using intra‐bladder administration (Oral Oxybutynin data sheet).
*2 Transdermal oxybutynin. The transdermal route is one of the tested forms of administration to minimize side effects along with the rectal route [8, 9]. The transdermal 
administration of oxybutynin avoids gastrointestinal metabolism and the hepatic first‐pass effect, which reduces the formation of the N‐desethyl metabolite, whose 
plasmatic concentration is directly related with the incidence of side effects associated with antimuscarinics. Its side effect profile is similar to the placebo except for the 
incidence of cutaneous reactions. This leads to a high degree of compliance (90–95%) [10] (Transdermal Oxybutynin data sheet).
*3 Tolterodine. Tolterodine is an anticholinergic agent with greater selectivity on the bladder than on the salivary glands, due to its more selective antimuscarinic effect on 
the M2 receptors, although it seems that the M3 glandular receptors are more sensitive to blocking [11, 12].
 The half‐life of oral tolterodine is approximately 6 h in fast metabolizers, and around 10 h in slow‐metabolizing patients (those lacking CYP2D6). The absolute bio‐
availability of tolterodine is 17% in fast metabolizers, which includes most patients, and 65% in slow‐metabolizing patients (Tolterodine data sheet).
*4 Solifenacin. The in vitro and in vivo pharmacological studies indicate that solifenacin is a competitive inhibitor specific to sub‐type M3 muscarinic receptors (Solifenacin 
data sheet).
*5 Fesoterodine. Fesoterodine is rapidly and extensively hydrolysed by unspecific plasmatic sterases, without undergoing the hepatic first‐pass effect, producing 5‐
hydroxymethyl derivatives, which is the main active metabolite and which makes it responsible for the pharmacological action of fesoterodine (Fesoterodine data sheet).
Table 1. Dosage and pharmacokinetic characteristics of the primary antimuscarinic drugs.
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2.3. Evidence: clinical efficacy
The efficacy of antimuscarinic drugs has been supported by five systematic reviews of differ‐
ent drugs compared to placebos [13–17]. Most of the studies include patients with an average 
age of 55–60 years, both men and women, where no results can be extrapolated based on sex. 
According to the evidence, and with significant consistency between the different studies, 
only moderate short‐term improvement of symptoms is observed with the use of antimusca‐
rinic drugs compared to placebo. See Table 2.
The best indicator of the relevance of the side effects is the rate of abandonment due to intol‐
erance, although this is not reflected in routine clinical practice. All of the formulations of 
fesoterodine, oxybutynin, propiverone, solifenacin, tolterodine, darifenacin and trospium 
offer a greater rate of improvement or resolution and a greater rate of side effects (dryness 
of the mouth) compared to placebo (Evidence Level (EL) 1a and 1b, respectively). Likewise, 
transcutaneous oxybutynin has shown a significant improvement in the number of episodes 
of incontinency and nocturnal urination per day compared to placebo, with improvement in 
urinary urgency, similar to its gel formulation [13].
2.4. Comparison between antimuscarinic drugs
The comparisons between the different antimuscarinic drugs, both in effectiveness and in side 
effects, are important for decision making in daily practice.
Forty randomized and controlled clinical trials have been published along with five system‐
atic reviews [13–15, 19, 20]. Almost all of them are studies supported by the pharmaceutical 
industry. Generally, the titration schemes of the dose are included in the protocols for the 
experimental group, but not for the comparison group. They are short studies (12 weeks) 
and the primary objective is the modification of the symptoms of OAB more than its cure or 
improvement in urinary urgency, generally analysed as a secondary objective. The clinical 
applicability of these studies in daily clinical practice is questionable as most of the studies 
are of low to average quality [16].
There is not enough evidence to confirm that one antimuscarinic drug is better than another to 
cure or improve urinary urgency (EL 1a). However, oxybutynin ER is superior to tolterodine 
Number of 
studies
N Relative Risk 
(95% CI)
Number of patients needed to 
treat NNT for a cure (95% CI)
Oxybutynin 
(IR–ER)
4 992 1.7 (1.3–2.1) 9 (6–16)
Tolterodine 
(IR–ER)
4 3404 1.2 (1.1–1.4) 12 (8–25)
Solifenacin 5 6304 1.5 (1.4–1.6) 9 (6–17)
Fesoterodine 2 2465 1.3 (1.1–1.5) 8 (5–17)
Table 2. Summary of the cure rate of the principal clinical trials [18].
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IR and ER (EL 1b), solifenacin is more effective than tolterodine IR (EL 1b) and fesoterodine is 
more effective than tolterodine ER (EL 1b), regarding improvement of urinary urgency. None 
of the antimuscarinic drugs have shown to improve the related quality of life better than the 
others (EL 1a) [16]. In general, it is accepted that if one antimuscarinic IR drug is not effective, 
an ER version is offered (grade of recommendation (GR A)).
The ER formulations cause less side effects than the IR formulations (EL 1b) [16, 20]. Oxybutynin 
IR produces more dryness of the mouth than tolterodine and trospium ER, but less than dari‐
fenacin [16, 20]. Oxybutynin ER generally produces more dryness of the mouth than toltero‐
dine ER, although the incidence of moderate to severe dryness of the mouth is similar (EL 1a). 
Transdermal oxybutynin has a lower rate of dryness of the mouth than oxybutynin IR and 
than tolterodine ER, but a greater rate of abandonment due to cutaneous reactions (EL 1b) [16]. 
In fact, the use of transdermal oxybutynin is recommended when oral antimuscarinic drugs 
are not tolerated due to dryness of the mouth (GR A). Solifenacin of 10 mg daily has a greater 
rate of dryness of the mouth than tolterodine four daily [21, 22]. The same rate of abandon‐
ment is generally observed, rewgardless of the incidence of dryness of the mouth. The primary 
comparative studies regarding the efficacy and adherence are shown in Table 3.
Performing an early check‐up of the efficacy and side effects after 1 month of treatment with 
these patients (GR A) is recommended. On the other hand, physicians should be able to man‐
age and treat the side effects inherent to antimuscarinic drugs (Tables 4 and 5). Patients must 
be informed regarding said effects before starting treatment.
2.5. Adherence: persistence
Most studies on antimuscarinic drugs have a short follow‐up period (12 weeks), considering 
that adherence in clinical trials is much higher than in routine practice [23].
The adherence rate at 2 years varies from 49 to 84% according to two clinical trials with fes‐
oterodine at 8 mg [24, 25]. The principal drugs studied regarding adherence are oxybutynin 
and tolterodine. The abandonment rate was very high after 12 months with tolterodine, but 
even higher with oxybutynin (68–95%).
Number of studies N Relative risk (95% CI)
Effectiveness
Oxybutynin ER vs. tolterodine 
ER
3 947 1.11 (0.94–1.31)
Solifenacin vs. tolterodine ER 1 1177 1.2 (1.08–1.34)
Fesoterodine vs. tolterodine 2 3312 1.1 (1.04–1.16)
Abandonment due to side effects
Solifenacin vs. tolterodine ER 3 2755 1.28 (0.86–1.91)
Fesoterodine vs. tolterodine 4 4440 1.54 (1.21–1.97)
Table 3. Comparison of the effectiveness and abandonment rate due to side effects of the principal antimuscarinic drugs 
[13].
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The average number of days before the drug is discontinued varies from 30 to 50 days [26]. In 
this sense, more than half of all patients will abandon treatment with antimuscarinics within 
the first 3 months due to lack of effectiveness, side effects or cost (EL 2).
Several randomized and controlled clinical trials have attempted to identify factors associated 
with a lower adherence rate. In this sense, the low level of efficacy (41.3%), adverse effects 
(22.4%) and cost (18.7%) [26] is associated with a lower adherence/persistence, along with IR 
formulations, age (young people), unrealistic expectations about treatment, gender (male) or 
race (Afro‐Americans and other minorities).
2.6. Cognitive effects in old age—anticholinergic load
Few studies in the elderly population with OAB are available and they present various limi‐
tations including the multi‐factorial aetiology of urinary urgency at this age, the presence of 
co‐morbidities such as cognitive deficit, the effect of concomitant medications or the high risk 
of suffering side effects. However, it can be confirmed that all antimuscarinic drugs are effec‐
tive in elderly patients (EL 1b).
The evidence is not conclusive regarding the cognitive effects of antimuscarinic drugs 
[27]. Few studies specifically study the cognitive changes associated with treatment using 
Symptomatic treatment of dry mouth
• Drink small sips of water
• Suck on sugar‐free hard candies or gum
• Avoid mouthwashes with alcohol
• Oral lubricants
‐ Anethole trithione (sialogogue)—one tablet three times per day (50% success rate)
‐ Bromhexine hydrochloride (sialogogue)—30 drops three times per day (60% success rate)
‐ Eledoisin (drops)—three drops under tongue when needed
‐ Artificial saliva—nebulizations when needed (94%)
‐ Squeezed lemon (sialogogue) —when needed
Table 4. Symptomatic treatment of dry mouth.
Symptomatic treatment of constipation
• Diet rich in fibre and liquids
• Fibre supplements
• Regular exercise
• Normal intestinal habits
Table 5. Symptomatic treatment of constipation.
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 antimuscarinics; in fact, there are no studies conducted on patients who are vulnerable to 
suffering cognitive deficit.
Regarding the primary antimuscarinic drugs used, the effects on the elderly population and 
on cognitive function are explained as follows:
• Oxybutynin. There is sufficient evidence to confirm that oxybutynin IR may cause or 
worsen cognitive deterioration, although there is no current consensus on this topic (EL 2) 
[28–34].
• Tolterodine. No differences in the efficacy or side effects have been reported regarding 
age [35–38], although a greater rate of abandonment has been reported in elderly patients 
compared with placebo [28]. On the other hand, the post hoc analysis showed a slight 
negative effect on cognitive function. That said, there is no evidence that tolterodine causes 
deterioration of cognitive function (EL 3).
• Solifenacin. A cluster analysis [33] has shown that treatment with solifenacin does not 
increase cognitive function in elderly patients. No pharmacokinetic differences have been 
demonstrated between the different age groups, although a greater frequency of side effects 
has been observed in patients over 80 years of age, without any cognitive effects identified 
in healthy volunteer patients [34]. In patients with moderate cognitive deterioration, over 
65 years of age, there were no differences in the efficacy between the different age groups, 
with a lower incidence of side effects in comparison with oxybutynin IR [33, 39]. Therefore, 
it can be confirmed that solifenacin has not shown to cause deterioration in cognitive func‐
tion in elderly patients (EL 1b).
• Fesoterodine. There is no evidence in the comparison of the efficacy and side effects of fes‐
oterodine between young and elderly patients. The cluster analysis of the different clinical 
trials confirmed the efficacy of fesoterodine at 8 mg but not at a dose of 4 mg in patients 
over 75 years of age. Adherence is lower in patients over 75 years of age; however, the 
effect on their mental state has not been documented [24, 40, 41]. There are no differences 
with the placebo regarding cognitive function in younger elderly patients [42]. Therefore, 
fesoterodine has not shown to cause deterioration in cognitive function in elderly patients 
(EL 1b).
Currently, extrapolating these data to the general elderly population is a risk. Conducting 
prevalence studies based on the community regarding the side effects of antimuscarinics 
could be very helpful in the future [43]. When antimuscarinic treatment is started in elderly 
patients, it is recommended that their mental function be evaluated objectively and monitored 
(GR C) [44]. Nonetheless, there is no consensus regarding which is the best test to evaluate 
mental function and detect changes in cognitive function [45, 46]. On the other hand, taking 
into account the so‐called ‘anticholinergic load’ (GR C) is important in older adults. Drugs 
with anticholinergic properties are commonly prescribed for a variety of medical illnesses 
[47–50]. It has been estimated that 20–50% of older people have been prescribed at least one 
medication with anticholinergic activity [49, 51]. This could be long‐term prescribed for con‐
ditions such as asthma or to manage the side effects of medicines used to treat psychiatric 
disorders [51]. That is why it is important to consider the anticholinergic load before starting a 
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treatment with anticholinergic drugs. In this aspect, the list of potentially inappropriate medi‐
cations (PIMs) determined by Beers Criteria in collaboration with the American Geriatrics 
Society [47] should be considered. These medications cause many problems, which are costly 
and often preventable in older adults and lead to poor outcomes. Some anticholinergic drugs, 
such as first‐generation antihistamines (dexchlorpheniramine, doxylamine and hydroxyzine), 
antiparkinson agents (benztropine and trihexyphenidyl) and antispasmodics (scopolamine 
and propantheline) are considered to be avoided in this population with moderated quality 
of evidence and strong recommendation [47], due to the wide spectrum of central effects such 
as the onset of dizziness, sedation, confusion, in addition to increasing delirium, causing a 
decline in cognitive and physical function [49–51]. In relation to urological anticholinergic 
drugs such as darifenacin, trospium, fesoterodin and solifenacin, these recommendations are 
softer, and they are usually associated to peripheral adverse effects such as chronic constipa‐
tion, dry mouth, dry eyes, blurred vision and increased heart rate [50]. Nevertheless, it is very 
important to estimate the anticholinergic load of each patient, in order to avoid the synergistic 
effect of several anticholinergic drugs, related to their tolerance and their well‐known side 
effects [47]. Furthermore, attention should also be paid when these drugs are combined with 
cholinesterase inhibitors, especially in elderly patients [45].
3. β3‐agonist: mirabegron
Mirabegron is the first clinical β3‐agonist available. The β3‐adrenergic receptors are the pre‐
dominant β‐receptors in the smooth muscle cells of the detrusor muscle and their stimulation 
leads to the relaxation of said muscle.
The clinical effectiveness of mirabegron is shown in two systematic revisions [52, 53], which 
demonstrate that the doses of 25, 50 and 100 mg reduce episodes of incontinency, episodes of 
urgency and urinary frequency in 24 h compared to placebo (EL 1a), with no differences in the 
frequency of side effects [52]. The continence rate (dryness) for the placebo is 35–40%, com‐
pared to 43–50% with mirabegron. In all of these studies, the significant statistical difference 
is observed in relation with improved symptoms, and not resolution (EL 1b). The effective‐
ness is similar both in those patients without previous treatment and in those that previously 
received treatment with antimuscarinics.
The effectiveness compared with extended release tolterodine 4 mg is practically identical 
with a continence rate (dryness) of 43–45% (EL 1b) [54].
The adrenergic side effects are somewhat frequent, without reaching levels of clinical 
relevance (EL 1a). The most frequent side effects are hypertension (7.3%), symptoms of 
nasopharyngitis (3.4%) and lower urinary tract infections (3%) [52]. No risks have been 
demonstrated with the prolongation of the QTc in electrocardiograms (ECGs) [55] nor with 
increased intra‐ocular pressure [56] observed with the dose of 100 mg. There are no signifi‐
cant differences in the rate of side effects depending on the different doses of mirabegron 
[54]. However, it is recommended that patients be informed of the possible long‐term side 
effects, which remain unknown (GR B).
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Evaluation of urodynamic parameters in patients with OAB together with obstructive symp‐
toms of bladder voiding concludes that mirabegron (50 or 100 mg) does not negatively affect 
said urodynamic voiding parameters compared with the placebo [57].
Regarding adherence, at 12 months, mirabegron presents a rate similar to that of toltero‐
dine (5.5 vs. 3.6%, respectively) (EL 1b), although the frequency of dry mouth is signifi‐
cantly greater in the tolterodine group [54]. There are no studies published on its use in 
elderly patients with OAB.
To summarize, mirabegron seems to provide a similar efficacy as that of the antimuscarinic 
drugs with a clearly lower rate of dry mouth and constipation. The low incidence of uncom‐
fortable side effects for the patient may make this the drug of choice in patients who have pre‐
viously suffered from dry mouth and/or constipation and/or who are currently being treated 
with antimuscarinics but are unable to tolerate them [4].
If symptom control is not adequate with antimuscarinic treatment or the side effects are intol‐
erable, along with regulating the dose, changing to a different antimuscarinic may be a suit‐
able alternative [4]. There are various observational studies on this topic, where unsatisfied 
patients treated with oxybutynin [58, 59] and tolterodine [58, 60, 61] showed greater effec‐
tiveness and/or greater tolerance with solifenacin [59, 60], fesoterodine [61] or darifenacin 
[58]. Also, these patients could also change to a β3‐adrenergic receptor antagonist such as 
mirabegron, with an efficacy profile similar to that of the antimuscarinic drugs but with less 
side effects.
The combination therapy with mirabegron and solifenacin has been evaluated previously [62]. 
Through a randomized, double‐blind, dose‐ranging, phase 2 study (called ‘SYMPHONY'), it 
was observed that different combination therapies, mirabegron 25 and 50 mg and solifenacin 
2.5, 5 and 10 mg, show significant improvements over monotherapy, solifenacin 5 mg, in rela‐
tion to the mean volume voided, number of micturitions per 24 h, incontinence episodes per 
24 h and urgency episodes per 24 h. All treatments were well tolerated and concordant with 
the known safety profile of mirabegron and solifenacin monotherapy. No dose‐related trends 
in blood pressure, pulse rate, post‐void residual volume or laboratory or ECG parameters 
were observed between groups, although the incidence of constipation was slightly increased 
with combination therapy. The lack of supra‐additive effects on safety parameters demon‐
strated that the mild pharmacokinetic interaction between mirabegron and solifenacin that 
was recently described [63] did not appear to be clinically relevant. So, the combination of 
mirabegron and solifenacin may provide an attractive therapeutic approach to maximize effi‐
cacy and minimize the side effect burden [62].
4. Botulinum toxin
Botulinum toxin is a presynaptic neuromuscular blocker that induces a selective and revers‐
ible muscle weakness that lasts up to 6 months. Botulinum toxin exercises its paralysing effect 
by inhibiting the release of acetylcholine from the motor nerve to the neuromuscular  junction. 
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It also decreases the afferent signals from the muscle spindles, which leads to it directly 
decreasing nerve activity that produces spasticity [64, 65].
The toxin marketed in Europe is onabotulinum toxin A (onabotA; BOTOX®), which is used at a 
dose of 100 IU dissolved in 10 ml of saline solution and injected in 20 spots on the bladder wall 
(0.5 ml per puncture site), over the trigone. It is indicated for the treatment of OAB with persis‐
tent or refractory urinary urgency in both sexes, in spite of the scarce number of male patients 
included in pre‐marketing trials [66, 67]. Other doses of onabotA and other formulations of botu‐
linum toxin A, abobotulinum toxin A and incobotulinum toxin A, have not been licensed for use 
in urinary urgency. Repeated injections are effective, with no decreased efficacy with repeated 
treatment (LE 3), but the percentage of patients who abandon treatment is high (EL 2). The most 
important side effects include episodes of lower urinary tract infection and increased post‐urina‐
tion and post‐voiding volume that may require the intermittent use of a bladder catheter [68].
By studying the effect of a staggered dose, it has been established that the ideal dose of onab‐
otA is 100 IU. The effectiveness of onabotA was shown in two randomized (1:1) phase III tri‐
als with a total of 1105 incontinent patients with OAB whose symptoms were not previously 
controlled with antimuscarinic treatment. In these studies, at the beginning, the population 
had an average of more than five episodes of urgent urinary incontinence (UUI), around 12 
urinations per day and a scarce post‐voiding volume. Twelve weeks after the endoscopic 
injection of onabotA, the episodes of UUI were reduced by half in treated patients, and to 
more than two, the number of urinations per day, with a total of 22.9% of patients com‐
pletely dry, compared with 6.5% of the group that received injections of saline solution (EL 
1a). Also, the patients’ quality of life was substantially improved in the group treated with 
onabotA compared to the control group (EL 1a) [69]. On the other hand, the cohort stud‐
ies have demonstrated the effectiveness of the injections in the bladder wall of onabotA in 
elderly patients [70], although the success rate was lower and the post‐voiding volume was 
greater (>150 ml) (EL 3).
One recent clinical trial compared the injection of 100 IU of onabotA compared with solifenacin 
and showed similar improvement in both groups regarding UUI after 6 months [71]. The patients 
who received onabotA were more inclined to resolution of the UUI (27% vs. 13%, p 0.003) (EL 1a), 
but with greater rates of urinary retention in the first 2 months (5% vs. 0%) and urinary tract infec‐
tion (33% vs. 13%). The patients who received solifenacin were more prone to suffer dry mouth.
In summary, offering endoscopic injections in the bladder wall with onabotulinum toxin A 
(100 U) in patients with refractory UUI after treatment with antimuscarinics (GR A) is recom‐
mended. The patients should be informed of the limited duration of the response, the risk of 
urinary tract infection and the possible need for posterior self‐catheterizations (GR A).
5. Sacral nerve stimulation
Nerve stimulation by means of the electrical stimulation of the sacral nerve roots is currently 
an accepted therapeutic alternative to treat chronic urinary dysfunction when other more con‐
servative options have failed. The development of nerve stimulation techniques has provided 
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a more physiologic and functional vision of functional disorders of the lower urinary tract by 
enabling the application of electric impulses that modify the behaviour of a specific affected 
neuronal system.
According to the Federal Drug Administration (FDA), the indications for sacral nerve stimula‐
tion are as follows:
• UUI, due to idiopathic, post‐surgical non‐obstructive hyperactivity bladder overactivity, 
associated with faecal incontinence or urethral overactivity.
• Voiding dysfunction, due to lack of contractility of the detrusor muscle, absence of relax‐
ation of the pelvic floor or Fowler's syndrome.
• Frequency‐urgency syndrome associated or not with pelvic pain, sensorial hyperactivity 
or chronic cystopathies.
• Interstitial cystitis and chronic urinary dysfunction from a neurological cause, spinal cord 
lesions, bladder sphincter dyssynergia and stable multiple sclerosis.
Although the mechanism of action of sacral nerve stimulation is yet to be completely estab‐
lished, it is known that the stimulation of the sacral nerves regulates the function of the detru‐
sor muscle and the external urinary sphincter through the inhibition or disinhibiting of the 
ventral inter‐neurons, modulating the sacral‐pontine reflexes that control urination. This is 
regulated through the efferent type A‐β‐ and A‐β‐somatic myelinated fibres that transmit the 
sensorial impulses from the metameres of the S2–S4 sacral roots [72–74].
Adequate evaluation of the patient is essential before taking into consideration the use of an 
implant to initiate nerve stimulation, with a basic neurourological examination and a uro‐
dynamic evaluation including a flowmetry, cystomanometry and electromyography of the 
surface of the perineum. This study should be performed before starting treatment, during 
the temporary stimulation test and after the definitive insertion of the implant.
The nerve stimulation implant is inserted in two surgical times, with the establishment of 
three phases in the initiation of the sacral nerve stimulation:
1. Evaluation of the sacral nerves. The percutaneous insertion is carried out with fluoro‐
scopic control using a stimulation electrode in the sacral foramen next to the sacral nerve, 
normally in S3. In the past, an electrode that was connected to an external stimuli genera‐
tor with a cable was used for 5–7 days. Currently, a tined electrode is used that allows 
for a longer test phase as it avoids mobilization of the system itself [75]. At this point, the 
integrity of the somatic motor and sensorial fibres of the sacral roots is evaluated. The 
motor response in S3 is the contraction of the pelvic floor as well as plantar flexion of the 
first toe of the foot. The sensitive response is a tingling sensation in the perineum and 
external genitals.
2. Sub‐chronic phase or test phase. In this phase, the therapeutic effect of the stimula‐
tion is determined through the daily urination of the patient during the stimulation. 
The patients who are candidates for the second surgical time for completion of the 
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 insertion of the pulse generator are those in which the UUI is reduced by more than 
50% during the test phase [76]. It has been found that the use of the serrated electrode 
in the initial implant increases the number of patients who end up with the definitive 
implant (EL 4).
3. Definitive implant. This consists of the percutaneous insertion of an electrode with four 
stimulation points that is implanted over the sacrum, fixing it to the periosteum and 
connecting it to the impulse generator placed in a subcutaneous pocket in the superior‐
external quadrant of the gluteus, or in the lower abdominal region [75]. The intervention 
is performed under general anaesthesia using short‐acting muscle relaxants to repro‐
duce the responses obtained in the evaluation of the sacral roots. The programming is 
performed within the first 24 h after the surgery using a telemetric programmer and 
selecting the individualized electric stimulation parameters of amplitude, frequency, 
pulse length and polarity. Also, the patient is given a hand programmer to activate or 
deactivate the generator and adjust the amplitude if needed.
All of the relevant randomized studies are affected by the limitation that neither the evalu‐
ators nor the patients were blinded for the active treatment decision, as all of the patients 
recruited for the implant had to have responded in the test phase prior to randomization.
Three clinical trials have been published regarding sacral nerve stimulation. One of them 
compared the implant with a control group that continued with medical treatment and 
delayed the implant by 6 months. Fifty per cent of the patients who were initially implanted 
experienced improvement of more than 90% in their UUI after 6 months compared to 1.6% of 
the control group [77]. Another clinical trial produced similar results; however, the effect on 
quality of life, evaluated using the SF‐36 questionnaire, was not conclusive, with differences 
between groups in only one of the eight domains [78].
Reviewing a total of 17 studies of a series of cases of patient with UUI treated in the begin‐
nings of the use of sacral nerve stimulation [79], we obtained the following results: after a 
follow‐up period of 1–3 years, approximately 50% of the patients experienced a reduction of 
more than 90% in their urinary urgency, 25% showed an improvement of 50–90% and another 
25% improved in less than 50%. In studies with a follow‐up period of at least 4 years, the con‐
tinued effectiveness of the treatment was observed, with an improvement of more than 50% 
of the initial symptoms in approximately 50% of the patients and a sustained resolution of 
symptoms in 15% (LE 3) [80, 81]. The resolution rate of UUI was 15% [81].
The incidence of adverse effects in relation with the implant is 50% [80, 81]. The most frequent 
adverse effect is the presence of pain at the site where the impulse generator is implanted 
(15.3%) followed by newly appearing pain (9%) and the migration of the electrode (8.4%) with 
the respective stimulation of undesired fibres and lack of effectiveness. These effects require 
surgical revision in 33–41% of cases [80, 81].
We can conclude that sacral nerve stimulation is more effective than maintaining conserva‐
tive treatment to cure UUI (EL 1b). If available, sacral nerve stimulation should be offered to 
patients with UUI refractory to conservative therapies.
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6. Posterior tibial nerve stimulation
Electro‐stimulation is included within the conservative therapies used to treat OAB by acting 
on the afferent nerves of the pelvic floor. When conducting a systematic review, two clinical 
trials compared the action of the electro‐stimulation with oxybutynin in patients with UUI, 
showing a similar efficacy between the two treatments [82].
Posterior tibial nerve stimulation is performed using a neuromodulator that utilizes the pero‐
neal nerve for afferent access to the S3 spinal cord region. The mechanism that makes the 
neuromodulation of the bladder‐urethra reflexes possible is based on the fact that the nerve 
fibres of the posterior tibial region share sensitive inputs with the S3 root. Current indications 
include overactive bladder with or without UUI and chronic pelvic pain.
The stimulation can be done in a percutaneous manner with a thin 34 G needle inserted just 
below the medial malleolus of the ankle (P‐PTNS), although it can also be done in a transcu‐
taneous manner (T‐PTNS). Adequate stimulation applied using the neuromodulator, regard‐
ing the frequency, intensity and length of the impulses, is demonstrated when the big toe 
is observed flexing or the remaining toes show extension or flexion. The normal treatment 
scheme consists of 12 weekly sessions of 30 min.
Regarding P‐PTNS and based on two clinical trials [83, 84], the results in women with refrac‐
tory OAB are consistent. The results suggest that this treatment improves UUI in women who 
have previously received treatment with antimuscarinics that was not effective or tolerable 
(EL 2b) (GR B). However, there is not enough evidence to confirm that P‐PTNS cures UUI or 
offers a long‐term solution for symptoms of OAB as the therapeutic effects dissipate when 
the treatment ends. On the other hand, P‐PTNS does not seem to be more effective than tolt‐
erodine in women (EL 1b) [85]. In men, there is no sufficient evidence to extract conclusions 
about its effectiveness.
Regarding T‐PTNS, a small clinical trial compared T‐PTNS together with standard treatment 
(rehabilitation of the pelvic floor and bladder training) with standard treatment used alone in 
elderly women. The group that received T‐PTNS showed more improvement of symptoms at 
the end of treatment [86]. However, the evidence on T‐PTNS is limited (EL 2a).
The side effects associated with this technique are infrequent and mild. The most common 
include cases of a painful feeling and transitory bleeding or bruising at the puncture site 
[87].
In routine clinical practice, finding patients on second‐line (drugs) or even third‐line treat‐
ment (botulinum toxin, PTNS or sacral nerve stimulation) that have not been correctly evalu‐
ated before starting said treatment, or that have never tried previous behaviour therapies, is 
common. Finding patients who have had little success with pharmacological treatment or 
with different combined simultaneous treatments without any clear evidence on the individ‐
ual efficacy of each therapy is also common. Patients must be reminded about the importance 
of persisting over time with a new treatment (from 4 to 8 weeks if the treatment is pharma‐
cological and from 8 to 12 weeks for behavioural therapies) to be able to clearly evaluate the 
efficacy and associated side effects before trying another line of treatment [4].
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7. Surgical treatments
Surgical treatment is reserved when all the non‐invasive therapies have not been effective. 
The first option is usually the augmentation cystoplasty, where a detubularized segment of 
bowel is inserted into the bivalved bladder wall. The distal ileum is the bowel segment most 
often used but any bowel segment can be used if it has the appropriate mesenteric length 
[88]. There are no randomized control trials comparing bladder augmentation to other treat‐
ments for patients with OAB. Most often, bladder augmentation is used to correct neurogenic 
OAB or small‐capacity, low‐compliant, bladders caused by fibrosis, tuberculosis, radiation 
or chronic infection. The largest case series of bladder augmentation in a mixed population 
of idiopathic and neurogenic OAB included 51 women [89], where only 53% were continent 
and satisfied with the surgery, whereas 25% had occasional leaks and 18% continued to have 
disabling OAB. It seems that the results for patients with idiopathic OAB (58%) seemed to 
be less satisfactory than for patients with neurogenic OAB (90%). Adverse effects were com‐
mon and many patients may require clean intermittent self‐catheterization to obtain adequate 
bladder emptying.
Another option is the detrusor myectomy. This technique aims to increase bladder capac‐
ity and reduce storage pressures by incising or excising a portion of the detrusor muscle, to 
create a pseudodiverticulum. Two case series [90, 91], in adult patients with idiopathic and 
neurogenic bladder dysfunction demonstrated poor long‐term results caused by fibrosis of 
this pseudodiverticulum. This technique is rarely used nowadays.
As the last alternative, urinary diversion remains a reconstructive option for patients who 
decline repeated surgery for OAB. However, there are no studies that have specifically exam‐
ined this technique in the treatment of non‐neurogenic OAB [88].
8. Future directions
Recently, studies have been conducted to find a biomarker for OAB to broaden the patho‐
physiological understanding of OAB. The biomarkers studied till today's date are the nerve 
growth factor [92], the corticotropin‐releasing factor [93], the prostaglandins [94] and inflam‐
matory factors such as the C‐reactive protein [95]. Another approach is to use high‐yield DNA 
array profiles to identify the expression of specific genes involved in OAB [96]; however, this 
approach is not directed and may offer too many non‐specific candidate biomarkers.
The sensorial or bladder and urethral input markers have also been studied using various 
methods. It remains unknown whether an ideal sensorial test for the lower urinary tract 
would have a clinical impact on the evaluation and management of OAB [97–99]. A recent 
review highlights the importance of the interaction of the bladder urothelium, the sub‐uro‐
thelium and the interstitial cells with afferent sensorial fibres [100]. The urothelium is defined 
as a cellular compartment for sensorial transduction with urothelial cells capable of releasing 
and responding to specific neurotransmitters, and communicating with the afferent nerve 
endings inside of the urothelium [101]. The compartments of the sub‐urothelium and the 
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detrusor muscle seem to contain pacemaker‐like cells, similar to the intestinal interstitial cells 
of Cajal, that modulate bladder contractility, rhythmicity and overactivity [102].
Both lines of research related with the basic science and translational research, once developed, 
will provide a greater understanding of the pathophysiological mechanisms of OAB, which 
would be of great help to find new therapeutic targets for the treatment of OAB syndrome.
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